Literature DB >> 25875327

Inhalation of the reactive aldehyde acrolein promotes antigen sensitization to ovalbumin and enhances neutrophilic inflammation.

Edmund O'Brien1, Page C Spiess1, Aida Habibovic1, Milena Hristova1, Robert A Bauer1, Matthew J Randall1, Matthew E Poynter2, Albert van der Vliet1.   

Abstract

Acrolein (ACR), an α,β-unsaturated aldehyde and a major component of tobacco smoke, is a highly reactive electrophilic respiratory irritant implicated in asthma pathogenesis and severity. However, few studies have directly investigated the influence of ACR exposure on allergen sensitization and pulmonary inflammation. The present study was designed to examine the impact of ACR inhalation on allergic sensitization to the inhaled antigen ovalbumin (OVA), as well as pulmonary inflammation during subsequent OVA challenge. Adult male C57BL/6 mice were exposed to inhaled OVA (1%, 30 min/day, 4 days/week) and/or ACR (5 ppm, 4 h/day, 4 days/week) over 2 weeks and subsequently challenged with aerosolized OVA (1%, 30 min/day) over three consecutive days. Serum anti-OVA IgG1 levels were increased significantly in animals exposed to both OVA and ACR, compared to animals exposed to either OVA or ACR alone. In addition, differential cell counts and histological analysis revealed an increase in BAL neutrophils in animals exposed to both OVA and ACR. However, exposure to both OVA and ACR did not influence mRNA expression of the cytokines il5, il10, il13 or tnfa, but significantly increased mRNA expression of ccl20. Moreover, ACR exposure enhanced lung mRNA levels of il17f and tgfb1, suggesting development of enhanced inhalation tolerance to OVA. Overall, the findings indicate that ACR inhalation can promote airway-mediated sensitization to otherwise innocuous inhaled antigens, such as OVA, but also enhances immune tolerance, thereby favoring neutrophilic airway inflammation.

Entities:  

Keywords:  Acrolein; allergic asthma; inflammation; ovalbumin

Mesh:

Substances:

Year:  2015        PMID: 25875327      PMCID: PMC4678038          DOI: 10.3109/1547691X.2015.1033571

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  62 in total

Review 1.  Recent advances in the pathophysiology of asthma.

Authors:  Desmond M Murphy; Paul M O'Byrne
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

Review 2.  The effects of acrolein on the thioredoxin system: implications for redox-sensitive signaling.

Authors:  Charles R Myers; Judith M Myers; Timothy D Kufahl; Rachel Forbes; Adam Szadkowski
Journal:  Mol Nutr Food Res       Date:  2011-08-03       Impact factor: 5.914

Review 3.  The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis.

Authors:  Stephen T Holgate; Graham Roberts; Hasan S Arshad; Peter H Howarth; Donna E Davies
Journal:  Proc Am Thorac Soc       Date:  2009-12

4.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids.

Authors:  S E Wenzel; S J Szefler; D Y Leung; S I Sloan; M D Rex; R J Martin
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

5.  Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma.

Authors:  V Siroux; I Pin; M P Oryszczyn; N Le Moual; F Kauffmann
Journal:  Eur Respir J       Date:  2000-03       Impact factor: 16.671

Review 6.  Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease.

Authors:  I Rahman; W MacNee
Journal:  Am J Physiol       Date:  1999-12

7.  Acrolein inhalation suppresses lipopolysaccharide-induced inflammatory cytokine production but does not affect acute airways neutrophilia.

Authors:  David Itiro Kasahara; Matthew E Poynter; Ziryan Othman; David Hemenway; Albert van der Vliet
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 8.  Second-hand tobacco smoke and cardiovascular disease risk: an epidemiological review.

Authors:  Andrew Dunbar; William Gotsis; William Frishman
Journal:  Cardiol Rev       Date:  2013 Mar-Apr       Impact factor: 2.644

Review 9.  Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms.

Authors:  S T Holgate; D E Davies; R M Powell; P H Howarth; H M Haitchi; J W Holloway
Journal:  Eur Respir J       Date:  2007-04       Impact factor: 16.671

10.  Impact of active and passive smoking as risk factors for asthma and COPD in women presenting to primary care in Syria: first report by the WHO-GARD survey group.

Authors:  Yousser Mohammad; Rafea Shaaban; Bassam Abou Al-Zahab; Nikolai Khaltaev; Jean Bousquet; Basim Dubaybo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-10-02
View more
  3 in total

1.  Acrolein and thiol-reactive electrophiles suppress allergen-induced innate airway epithelial responses by inhibition of DUOX1 and EGFR.

Authors:  Karamatullah Danyal; Willem de Jong; Edmund O'Brien; Robert A Bauer; David E Heppner; Andrew C Little; Milena Hristova; Aida Habibovic; Albert van der Vliet
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-09       Impact factor: 5.464

2.  Janus-faced Acrolein prevents allergy but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse model for passive respiratory exposure.

Authors:  Franziska Roth-Walter; Cornelia Bergmayr; Sarah Meitz; Stefan Buchleitner; Caroline Stremnitzer; Judit Fazekas; Anna Moskovskich; Mario A Müller; Georg A Roth; Krisztina Manzano-Szalai; Zdenek Dvorak; Alina Neunkirchner; Erika Jensen-Jarolim
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

Review 3.  Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review.

Authors:  Agnieszka Strzelak; Aleksandra Ratajczak; Aleksander Adamiec; Wojciech Feleszko
Journal:  Int J Environ Res Public Health       Date:  2018-05-21       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.